In vivo and in vitro analysis shows AdipoRon decreases hepatic fat in broilers, indicating potential for fatty liver syndrome treatment.
To investigate the effects of AdipoRon on fatty liver syndrome (FLS) in chicken, we used a corticosterone (CORT)-induced fatty liver model in Cobb broilers in vivo and fat emulsion-induced model in Leghorn male hepatoma cells (LMH) in vitro . In the in vivo study, eighteen 33-day-old male Cobb broilers were randomly assigned to three groups: control group (CONT, vehicle), corticosterone-treated group (CORT, 4 mg/kg), and corticosterone with AdipoRon-treated group (CORT-AR, 4 mg/kg and 0.2 mg/kg, 1 time/1 day) for 5 days. The results showed AdipoRon reduced CORT-induced increase in liver crude fat content ( p < 0.05), increased protein expressions of peroxisome proliferator-activated receptor α (PPARα) ( p < 0.05) and adiponectin (ADPN) ( p < 0.05), and suppressed the protein expressions of Acetyl-CoA carboxylase 1 (ACC) ( p < 0.05) and phosphorylated c-Jun N-terminal kinase 1 (p-JNK1) ( p < 0.05) in the liver. In the in vitro study, LMH cells were divided into control (CN), fat emulsion (FE, 10%), and FE + AdipoRon (4 μM) group (FE-AR). AdipoRon reduced FE-induced lipid accumulation ( p < 0.05), decreased the protein expression of ACC and tumor necrosis factor-alpha (TNF- α ), and enhanced PPARα, the phosphorylation of adenosine 5′-monophosphate-activated protein kinase (AMPK), and carnitine palmitoyl transferase 1 (CPT-1) ( p < 0.05). In conclusion, AdipoRon effectively reduces hepatic lipid deposition in CORT-induced FLS broilers, likely through PPARα activation and inhibition of lipid synthesis via ACC downregulation.
No takes yet. Share an insight, caveat, or question.
Tan et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: